It is my understanding that a pharmaceutical manufacturer is responsible for the clinical papers that a Rep has access to i.e., in their bag or on their iPad. If nothing is being done to change or enhance the clinical paper in any way (to brand it as an example) then the clinical paper does not need to be sent to PAAB and the manufacturer takes responsibility for the papers that a Rep holds. Please confirm.
Jennifer Carroll last edited by
@jennifer-carroll Many thanks